コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 /F/tenofovir alafenamide and 867 given E/C/F/tenofovir disoproxil fumarate).
2 amide and 437 with efavirenz, emtricitabine, tenofovir disoproxil fumarate).
3 men (both regimens include emtricitabine and tenofovir disoproxil fumarate).
4 (581 with tenofovir alafenamide and 292 with tenofovir disoproxil fumarate).
5 namide and 19 [7%] of 288 patients receiving tenofovir disoproxil fumarate).
6 despite consistent use of emtricitabine and tenofovir disoproxil fumarate.
7 improved renal and bone safety compared with tenofovir disoproxil fumarate.
8 in patients switched from emtricitabine with tenofovir disoproxil fumarate.
9 n with initiation of efavirenz/emtricitabine/tenofovir disoproxil fumarate.
10 non-inferiority of tenofovir alafenamide to tenofovir disoproxil fumarate.
11 osted protease inhibitor, emtricitabine, and tenofovir disoproxil fumarate.
12 remaining on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate.
13 ir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate.
14 versus in those remaining on one containing tenofovir disoproxil fumarate.
15 n coformulated efavirenz, emtricitabine, and tenofovir disoproxil fumarate.
16 argin of tenofovir alafenamide compared with tenofovir disoproxil fumarate.
17 fenamide 0.01 mg/dL [95% CI 0.00 to 0.02] vs tenofovir disoproxil fumarate 0.02 mg/dL [0.00 to 0.04],
18 creatinine increases than those given E/C/F/tenofovir disoproxil fumarate (0.08 vs 0.12 mg/dL; p<0.0
19 21 were in those assigned emtricitabine plus tenofovir disoproxil fumarate (0.48 cases per 100 person
20 (tenofovir alafenamide 40 [14%] patients vs tenofovir disoproxil fumarate 14 [10%] patients), nasoph
21 r (400/100 mg) twice daily and emtricitabine/tenofovir disoproxil fumarate (200/300 mg) once daily.
22 mly assigned (1:1) to receive daily combined tenofovir disoproxil fumarate (245 mg) and emtricitabine
23 , 200 mg, or 400 mg once a day or to receive tenofovir disoproxil fumarate 300 mg once a day; each al
24 oral doses of tenofovir alafenamide 25 mg or tenofovir disoproxil fumarate 300 mg, each with matching
25 ) ritonavir (RTV) or standard of care (SOC) (tenofovir disoproxil fumarate 300 mg, emtricitabine 200
26 rticipants were given combination tablets of tenofovir disoproxil fumarate (300 mg) and emtricitabine
27 ivirine (25 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarate (300 mg), with matching pl
28 virenz (600 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarate (300 mg), with matching pl
31 ted with each additional year of exposure to tenofovir disoproxil fumarate (adjusted incidence rate r
32 was not significantly different from that of tenofovir disoproxil fumarate alone (hazard ratio [HR] 0
33 ir, either as a vaginal gel or as daily oral tenofovir disoproxil fumarate, alone or coformulated wit
34 ated metabolites of abacavir, emtricitabine, tenofovir disoproxil fumarate, amdoxovir, and zidovudine
35 ety and efficacy of daily oral emtricitabine-tenofovir disoproxil fumarate among HIV-seronegative men
36 Tanzania to receive either a combination of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC
37 seronegative men and women to receive either tenofovir disoproxil fumarate and emtricitabine (TDF-FTC
41 f pre-exposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine in 2499
42 tonavir-boosted atazanavir plus coformulated tenofovir disoproxil fumarate and emtricitabine once a d
43 th darunavir/ritonavir and 2 nucleos(t)ides (tenofovir disoproxil fumarate and emtricitabine or abaca
44 g (one tablet) orally twice daily, each with tenofovir disoproxil fumarate and emtricitabine orally o
45 lled three-group phase 3 trial of daily oral tenofovir disoproxil fumarate and emtricitabine plus ten
46 atinine clearance and the number of doses of tenofovir disoproxil fumarate and emtricitabine taken pe
47 Patients started RAL in combination with tenofovir disoproxil fumarate and lamivudine after initi
48 BMS-986001 had similar efficacy to that of tenofovir disoproxil fumarate and was associated with a
49 ir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate and were followed up for H
50 amide and 36 [13%] of 288 patients receiving tenofovir disoproxil fumarate) and AST (20 [3%] of 577 p
52 ovir alafenamide was non-inferior to that of tenofovir disoproxil fumarate, and had improved bone and
53 n, tenofovir alafenamide was non-inferior to tenofovir disoproxil fumarate, and had improved bone and
54 mbination of lopinavir/ritonavir, efavirenz, tenofovir disoproxil fumarate, and lamivudine and compar
55 l density than a standard regimen containing tenofovir disoproxil fumarate, and might be a treatment
56 ks, viral genotypes for nonresponders in the tenofovir disoproxil fumarate arm showed M184V or I/M/V
57 occurred in 50 (49%) of 102 subjects in the tenofovir disoproxil fumarate arm, compared with 5 (5%)
61 bolite to target cells more efficiently than tenofovir disoproxil fumarate at a lower dose, thereby r
62 /ADAPT) of oral PrEP with emtricitabine plus tenofovir disoproxil fumarate at a research centre in Ca
63 lso extend to HIV-negative individuals using tenofovir disoproxil fumarate-based pre-exposure prophyl
64 il fumarate compared with emtricitabine plus tenofovir disoproxil fumarate, but show that once-daily
67 elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate compared with a boosted pr
68 a slight difference in HIV-1 protection with tenofovir disoproxil fumarate compared with emtricitabin
69 d trial of PrEP with oral emtricitabine plus tenofovir disoproxil fumarate compared with placebo in m
71 ) or to carry on taking one of four previous tenofovir disoproxil fumarate-containing regimens (tenof
72 min or greater, and were taking one of four tenofovir disoproxil fumarate-containing regimens for at
74 placebo-controlled intensification trials of tenofovir disoproxil fumarate (DF) in treatment-experien
77 omly assigned to receive either a regimen of tenofovir disoproxil fumarate (DF), emtricitabine, and e
78 group) or combination therapy with efavirenz-tenofovir disoproxil fumarate (DF)-emtricitabine once da
79 for HIV-1 infection: abacavir-lamivudine or tenofovir disoproxil fumarate (DF)-emtricitabine plus ef
81 of 4 animals received oral topical doses of tenofovir disoproxil fumarate (DF; equivalent to 0.037 m
83 articipants were randomized 1:1:1 to receive tenofovir-disoproxil fumarate (DF) plus emtricitabine, a
84 disoproxil fumarate; one patient assigned to tenofovir disoproxil fumarate did not receive the treatm
85 8 versus 130 (93%) of 140 patients receiving tenofovir disoproxil fumarate (difference 1.8% [95% CI -
86 mide (E/C/F/tenofovir alafenamide) or 300 mg tenofovir disoproxil fumarate (E/C/F/tenofovir disoproxi
88 wer among infants exposed from conception to tenofovir disoproxil fumarate, emtricitabine, and efavir
89 aive participants were randomized to receive tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) pl
90 This study estimated the number of daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) do
91 phylaxis (PrEP) interventions worldwide, yet tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) fo
92 ment-naive individuals randomized equally to tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) pl
94 re associated with suboptimal adherence, and tenofovir disoproxil fumarate/emtricitabine was associat
95 se inhibitors (NRTIs; abacavir/lamivudine or tenofovir disoproxil fumarate/emtricitabine) and a third
97 acy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF) with that
98 r alafenamide and 12 (4%) patients receiving tenofovir disoproxil fumarate experienced serious advers
99 men and had been on daily emtricitabine and tenofovir disoproxil fumarate for 8 months presented wit
100 ies per mL) on efavirenz, emtricitabine, and tenofovir disoproxil fumarate for at least 6 months befo
101 s per mL) on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate for at least 6 months befo
102 fumarate (TDF) and combination emtricitabine/tenofovir disoproxil fumarate (FTC+TDF), is efficacious
103 oral antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC-TDF), or placebo once
104 ated that combination oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) as preexposure p
105 ophylaxis (PrEP) with oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) decreases the ri
106 posure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) is a novel strat
108 e prophylaxis (PrEP) with emtricitabine plus tenofovir disoproxil fumarate (FTC/TDF) or TDF alone red
109 p<0.0001) and 93% for the emtricitabine plus tenofovir disoproxil fumarate group (0.07, 0.02-0.23; p<
110 amide group and in 444 (93%) assigned to the tenofovir disoproxil fumarate group (adjusted difference
111 enamide group compared with 307 (93%) in the tenofovir disoproxil fumarate group (difference 1.3%, 95
112 risk reduction in HIV-1 acquisition for the tenofovir disoproxil fumarate group (HR 0.15, 95% CI 0.0
113 per mL, compared with 88 (89%) of 99 in the tenofovir disoproxil fumarate group (modified intention-
114 lated to study treatment; one patient in the tenofovir disoproxil fumarate group died, but this was n
115 fovir alafenamide (2%) and three (1%) in the tenofovir disoproxil fumarate group discontinued due to
116 de group and 96 (33%) of 292 patients in the tenofovir disoproxil fumarate group had grade 3 or 4 lab
117 ruption and thrombocytopenia) and two in the tenofovir disoproxil fumarate group had study drug-relat
118 e group and 784 (90%) of 867 patients in the tenofovir disoproxil fumarate group having plasma HIV-1
124 e group compared with 37 (12%) of 314 in the tenofovir disoproxil fumarate group; none of these were
125 enofovir alafenamide and 294 (94%) of 313 on tenofovir disoproxil fumarate had maintained less than 5
126 alafenamide and nine (6%) patients receiving tenofovir disoproxil fumarate had serious adverse events
127 s given E/C/F/tenofovir alafenamide or E/C/F/tenofovir disoproxil fumarate had virological success.
129 in bone mineral density than those receiving tenofovir disoproxil fumarate (hip -0.29% [95% CI -0.55
130 daily oral tenofovir disoproxil fumarate or tenofovir disoproxil fumarate in combination with emtric
131 or to continuing rilpivirine, emtricitabine, tenofovir disoproxil fumarate in maintaining viral suppr
132 the efficacy and safety of BMS-986001 versus tenofovir disoproxil fumarate in treatment-naive patient
134 ections, 31 occurred in individuals assigned tenofovir disoproxil fumarate (incidence 0.71 cases per
136 elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (integrase inhibitor regim
139 re prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate is highly effective agains
141 ophylaxis (PrEP) with oral emtricitabine and tenofovir disoproxil fumarate is used to prevent the sex
144 nt with efavirenz and lamivudine plus either tenofovir disoproxil fumarate (n=55) or stavudine (n=45)
145 enamide vs 22 [8%] of 292 patients receiving tenofovir disoproxil fumarate), nasopharyngitis (56 [10%
146 mg of raltegravir twice daily and 300 mg of tenofovir disoproxil fumarate once daily as a backbone.
147 to tenofovir alafenamide and 141 assigned to tenofovir disoproxil fumarate; one patient assigned to t
149 should be followed; adjustment should avoid tenofovir disoproxil fumarate or boosted protease inhibi
150 re offered rerandomisation in a 1:1 ratio to tenofovir disoproxil fumarate or emtricitabine plus teno
152 oxil fumarate, but show that once-daily oral tenofovir disoproxil fumarate or emtricitabine plus teno
153 ts taking antiretroviral regimens containing tenofovir disoproxil fumarate or other nucleoside analog
154 exposure prophylaxis (PrEP), with daily oral tenofovir disoproxil fumarate or tenofovir disoproxil fu
155 hylaxis (PrEP), using daily oral combination tenofovir disoproxil fumarate plus emtricitabine, is an
157 idanosine-EC, n = 293), and C (emtricitabine-tenofovir-disoproxil fumarate plus efavirenz, n = 278) a
158 tor-selected regimen of background N(t)RTIs (tenofovir-disoproxil-fumarate plus emtricitabine, zidovu
159 open-label study of daily oral emtricitabine-tenofovir disoproxil fumarate PrEP among 50 HIV-uninfect
160 r disoproxil fumarate and emtricitabine plus tenofovir disoproxil fumarate PrEP in HIV-1 uninfected i
161 ir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate (protease inhibitor based
162 regimen and 402 (92%) of 437 assigned to the tenofovir disoproxil fumarate regimen (difference -2.0%,
163 eived one dose of study drug and were on the tenofovir disoproxil fumarate regimen before screening w
164 ir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate regimens both provide high
165 We assessed the efficacy of single-agent tenofovir disoproxil fumarate relative to combination em
167 sease associated with cumulative exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazana
168 e increased for up to 6 years of exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazana
169 iled macaques were treated with a regimen of tenofovir disoproxil fumarate, saquinavir, atazanavir, a
170 After adjustment, persons who had ever used tenofovir disoproxil fumarate (TDF) (1.40; 1.15-1.70) or
171 prophylaxis (PrEP) using the antiretroviral tenofovir disoproxil fumarate (TDF) alone or in combinat
173 oviral preexposure prophylaxis (PrEP), using tenofovir disoproxil fumarate (TDF) and combination emtr
174 e randomly assigned to take a combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (F
175 ibitor (NNRTI) based FDC of rilpivirine plus tenofovir disoproxil fumarate (TDF) and emtricitabine (F
177 emtricitabine (FTC), rilpivirine (RPV), and tenofovir disoproxil fumarate (TDF) as a 3-drug, single-
178 ected with HIV and HBV who were treated with tenofovir disoproxil fumarate (TDF) as part of highly ac
179 viral therapy currently receive some form of tenofovir disoproxil fumarate (TDF) as part of their HIV
180 phylaxis (PrEP) with emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) can partially preven
181 chnology that delivers the tenofovir prodrug tenofovir disoproxil fumarate (TDF) continuously over 28
184 cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) in a single tablet g
185 itis B e antigen positive patients receiving tenofovir disoproxil fumarate (TDF) in an open-label, lo
189 ATV) in combination with emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in treatment-naive p
190 cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) into a once-daily, s
200 from patients with rapid or slow response to tenofovir disoproxil fumarate (TDF) treatment, have been
203 differ among patients receiving LDV/SOF and tenofovir disoproxil fumarate (TDF) without a protease i
206 lone, MVC plus emtricitabine (FTC), MVC plus tenofovir disoproxil fumarate (TDF), and TDF plus FTC.
208 nd 7 had M184V/I (0.1%), despite high use of tenofovir disoproxil fumarate (TDF), emtricitabine, and
209 ug of tenofovir and a potential successor of tenofovir disoproxil fumarate (TDF), has been approved i
210 ed trial to assess daily treatment with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtr
212 l to demonstrate that a novel gel containing tenofovir disoproxil fumarate (TDF), the more potent pro
213 ophylaxis (PrEP) with a novel gel containing tenofovir disoproxil fumarate (TDF), the tenofovir prodr
216 importance of renal and endocrine changes in tenofovir disoproxil fumarate (TDF)-related bone toxicit
221 men with symptomatic HSV-2 infection to oral tenofovir disoproxil fumarate (TDF)/placebo vaginal gel,
222 andomly assigned to groups given either oral tenofovir disoproxil fumarate (TDF, 300 mg) and placebo
223 (PrEP) with Truvada (emtricitabine [FTC] and tenofovir disoproxil fumarate [TDF]) is a novel HIV prev
225 elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (tenofovir) might be a saf
226 ed protease inhibitor and emtricitabine plus tenofovir disoproxil fumarate (tenofovir) regimen to cof
228 r plasma concentrations by 90% compared with tenofovir disoproxil fumarate, thereby decreasing bone a
229 cells more efficiently at a lower dose than tenofovir disoproxil fumarate, thereby reducing systemic
230 n patients switching from emtricitabine with tenofovir disoproxil fumarate to emtricitabine with teno
232 ovir regimens, each for 6 weeks (oral 300 mg tenofovir disoproxil fumarate, vaginal 1% tenofovir gel
233 randomized, open-label, multicenter study of tenofovir disoproxil fumarate versus efavirenz, both adm
234 amide-containing regimen from one containing tenofovir disoproxil fumarate was non-inferior for maint
235 afenamide from efavirenz, emtricitabine, and tenofovir disoproxil fumarate was non-inferior in mainta
236 prevention efficacy with emtricitabine plus tenofovir disoproxil fumarate was not significantly diff
237 ndividuals on cART (predominantly containing tenofovir disoproxil fumarate) were also more likely to
238 e 200 mg emtricitabine with 200 mg or 300 mg tenofovir disoproxil fumarate, while remaining on the sa
239 erior to the 195 (67%) of patients receiving tenofovir disoproxil fumarate who had HBV DNA less than
240 either 25 mg tenofovir alafenamide or 300 mg tenofovir disoproxil fumarate with matching placebo.
241 300 mg tenofovir disoproxil fumarate (E/C/F/tenofovir disoproxil fumarate) with matching placebo.
242 ofovir alafenamide was non-inferior to E/C/F/tenofovir disoproxil fumarate, with 800 (92%) of 866 pat
243 tenofovir alafenamide was as efficacious as tenofovir disoproxil fumarate, with reduced bone and ren
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。